Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus TRIFERIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus TRIFERIC.
ACCRUFER vs TRIFERIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
Triferic (ferric pyrophosphate citrate) is an iron replacement agent that delivers iron directly to transferrin via the sodium-dependent phosphate transporter, bypassing the reticuloendothelial system, thereby increasing iron availability for erythropoiesis without increasing ferritin levels.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
For iron deficiency anemia: 1 tablet (30 mg elemental iron as ferric pyrophosphate citrate) twice daily, 30 minutes before meals, administered orally.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
The terminal elimination half-life of ferric carboxymaltose is approximately 7-12 hours for the iron-carbohydrate complex. However, the clinical context involves redistribution of iron to stores and erythron, with a functional half-life of about 14-21 days for iron utilization.
Renal 65% (as unchanged drug), fecal 35%
Ferric carboxymaltose is eliminated primarily via renal excretion of the iron-carbohydrate complex, with approximately 60-70% of the administered iron dose excreted in urine within 24 hours. The remaining 30-40% is retained in the body, incorporated into hemoglobin and iron stores, with minimal biliary or fecal excretion.
Category C
Category C
Iron Replacement
Iron Replacement